Skip to main content
SpringerLink
Log in

Schizophrenia and Gender

  • Chapter
  • First Online:
Psychopathology in Women

Abstract

The existence of significant differences in schizophrenia is an issue that has been discussed extensively. There are differences in the prognosis, marked by the age at onset, treatment adherence, or drug use. Another aspect is the clinical pattern (particularly cognitive symptoms), the response to treatment, and side effects. These differences can be explained on the basis of biological and psychosocial hypotheses. Schizophrenia is a very heterogeneous disorder if we consider its basic clinical characteristics. That heterogeneity is shown by the vast variability in the onset and clinical presentation, the course of the illness, and response to both pharmacological and psychosocial treatment. That heterogeneity may be due to gender-related features, or at least gender variables may help to understand those differences. For this reason, gender differences in schizophrenia have been widely studied in past few decades. Unfortunately, research for many of those differences has not been conclusive.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 119.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 159.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Ochoa S, Usall J, Cobo J, Labad X, Kulkarni J. Gender differences in schizophrenia and first-episode psychosis: a comprehensive literature review. Schizophr Res Treatment. 2012;2012:916198. doi:10.1155/2012/916198. Epub 2012 Apr 8.

    PubMed  PubMed Central  Google Scholar 

  2. Aleman A, Kahn RS, Selten JP. Sex differences in the risk of schizophrenia: evidence from meta-analysis. Arch Gen Psychiatry. 2003;60(6):565–71.

    PubMed  Google Scholar 

  3. Zhang XY, da Chen C, Xiu MH, Yang FD, Haile CN, Kosten TA, Kosten TR. Gender differences in never-medicated first-episode schizophrenia and medicated chronic schizophrenia patients. J Clin Psychiatry. 2012;73(7):1025–33. doi:10.4088/JCP.11m07422.

    PubMed  Google Scholar 

  4. McEvoy JP, Meyer JM, Goff DC, Nasrallah HA, Davis SM, Sullivan L, Meltzer HY, Hsiao J, Scott Stroup T, Lieberman JA. Prevalence of the metabolic syndrome in patients with schizophrenia: baseline results from the clinical antipsychotic trials of intervention effectiveness (CATIE) schizophrenia trial and comparison with national estimates from NHANESIII. Schizophr Res. 2005;80(1):19–32. Epub 2005 Aug 30.

    PubMed  Google Scholar 

  5. Chan RC, Chen EY, Cheung EF, Chen RY, Cheung HK. The components of executive functioning in a cohort of patients with chronic schizophrenia: a multiple single-case study design. Schizophr Res. 2006;81(2–3):173–89. Epub 2005 Sep 26.

    PubMed  Google Scholar 

  6. Usall J, Busquets E, Araya S, Ochoa S, Gost A. Gender differences in schizophrenia. A literature review. Actas Esp Psiquiatr. 2000;28(3):178–85.

    PubMed  CAS  Google Scholar 

  7. Häfner H, Maurer K, Löffler W, Fätkenheuer B, an der Heiden W, Riecher-Rössler A, Behrens S, Gattaz WF. The epidemiology of early schizophrenia. Influence of age and gender on onset and early course. Br J Psychiatry Suppl. 1994;23:29–38.

    PubMed  Google Scholar 

  8. Kirov G, Jones PB, Harvey I, Lewis SW, Toone BK, Rifkin L, Sham P, Murray RM. Do obstetric complications cause the earlier age at onset in male than female schizophrenics? Schizophr Res. 1996;20(1–2):117–24.

    PubMed  CAS  Google Scholar 

  9. Verdoux H, Bourgeois M. A comparative study of obstetric history in schizophrenics, bipolar patients and normal subjects. Schizophr Res. 1993;9(1):67–9.

    PubMed  CAS  Google Scholar 

  10. Forsyth JK, Ellman LM, Tanskanen A, Mustonen U, Huttunen MO, Suvisaari J, Cannon TD. Genetic risk for schizophrenia, obstetric complications, and adolescent school outcome: evidence for gene-environment interaction. Schizophr Bull. 2013;39(5):1067–76. doi:10.1093/schbul/sbs098. Epub 2012 Sep 1.

    PubMed  PubMed Central  Google Scholar 

  11. Preti A, Cardascia L, Zen T, Marchetti M, Favaretto G, Miotto P. Risk for obstetric complications and schizophrenia. Psychiatry Res. 2000;96(2):127–39.

    PubMed  CAS  Google Scholar 

  12. Goldstein JM, Faraone SV, Chen WJ, Tolomiczencko GS, Tsuang MT. Sex differences in the familial transmission of schizophrenia. Br J Psychiatry. 1990;156:819–26.

    PubMed  CAS  Google Scholar 

  13. Pulver AE, Liang KY. Estimating effects of proband characteristics on familial risk. The association between age at onset and familial risk in the Maryland schizophrenia sample. Genet Epidemiol. 1991;8(5):339–50.

    PubMed  CAS  Google Scholar 

  14. Maier W, Lichtermann D, Minges J, Heun R, Halmayer J. The impact of gender and age at onset on the familial aggregation of schizophrenia. Eur Arch Psychiatry Clin Neurosci. 1993;242(5):279–85.

    PubMed  CAS  Google Scholar 

  15. González-Pinto A, Vega P, Ibáñez B, Mosquera F, Barbeito S, Gutiérrez M, Ruiz de Azúa S, Ruiz I, Vieta EJ. Impact of cannabis and other drugs on age at onset of psychosis. J Clin Psychiatry. 2008;69(8):1210–6.

    PubMed  Google Scholar 

  16. Foti DJ, Kotov R, Guey LT, Bromet EJ. Cannabis use and the course of schizophrenia: 10-year follow-up after first hospitalization. Am J Psychiatry. 2010;167(8):987–93.

    PubMed  PubMed Central  Google Scholar 

  17. Barnes TRE, Mutsatsa SH, Hutton SB, Watt HC, Joyce EM. Comorbid substance use and age at onset of schizophrenia. Br J Psychiatry. 2006;188:237–42.

    PubMed  Google Scholar 

  18. Rodríguez-Jiménez R, Aragüés M, Jiménez-Arriero MA, et al. Dual diagnosis in psychiatric in patients: prevalence and general characteristics. Invest Clin. 2008;49(2):195–205.

    PubMed  Google Scholar 

  19. Galderisi S, Bucci P, Üçok A, Peuskens J. No gender differences in social outcome in patients suffering from schizophrenia. Eur Psychiatry. 2012;27(6):406–8.

    PubMed  CAS  Google Scholar 

  20. Arendt M, Rosenberg R, Foldager L, Perto G, Munk-Jørgensen P. Cannabis-induced psychosis and subsequent schizophrenia-spectrum disorders: follow-up study of 535 incident cases. Br J Psychiatry. 2005;187:510–5.

    PubMed  Google Scholar 

  21. Thorup A, Albert N, Bertelsen M, et al. Gender differences in first-episode psychosis at 5-year follow-up—two different courses of disease? Results from the OPUS study at 5-year follow-up. Eur Psychiatry. 2014;29(1):44–51.

    PubMed  CAS  Google Scholar 

  22. González-Pinto A, Alberich S, Ruiz de Azúa S, Martínez-Cengotitabengoa M, Fernández M, Gutiérrez M, Saenz M, Besga A, Galdós P, de Leon J. Psychosis and smoking cessation: difficulties in quitting associated with sex and substance abuse. Psychiatry Res. 2012;195(1–2):45–50.

    PubMed  Google Scholar 

  23. Salokangas RK. Prognostic implications of the sex of schizophrenic patients. Br J Psychiatry. 1983;142:145–51.

    PubMed  CAS  Google Scholar 

  24. Shtasel DL, Gur RE, Gallacher F, Heimberg C, Gur RC. Gender differences in the clinical expression of schizophrenia. Schizophr Res. 1992;7(3):225–31.

    PubMed  CAS  Google Scholar 

  25. Tang YL, Gillespie CF, Epstein MP, Mao PX, Jiang F, Chen Q, Cai ZJ, Mitchell PB. Gender differences in 542 Chinese inpatients with schizophrenia. Schizophr Res. 2007;97(1–3):88–96. Epub 2007 Jul 12.

    PubMed  Google Scholar 

  26. Allen DN, Strauss GP, Barchard KA, Vertinski M, Carpenter WT, Buchanan RW. Differences in developmental changes in academic and social premorbid adjustment between males and females with schizophrenia. Schizophr Res. 2013;146(1–3):132–7. doi:10.1016/j.schres.2013.01.032. Epub 2013 Mar 13.

    PubMed  PubMed Central  Google Scholar 

  27. Häfner H. Gender differences in schizophrenia. Psychoneuroendocrinology. 2003;28 Suppl 2:17–54.

    PubMed  Google Scholar 

  28. Krysta K, Murawiec S, Klasik A, Wiglusz MS, Krupka-Matuszczyk I. Sex-specific differences in cognitive functioning among schizophrenic patients. Psychiatr Danub. 2013;25 Suppl 2:244–6.

    Google Scholar 

  29. Halari R, Mehrotra R, Sharma T, Ng V, Kumari V. Cognitive impairment but preservation of sexual dimorphism in cognitive abilities in chronic schizophrenia. Psychiatry Res. 2006;141(2):129–39. Epub 2006 Jan 19.

    PubMed  Google Scholar 

  30. Abu-Akel A, Bo S. Superior mentalizing abilities of female patients with schizophrenia. Psychiatry Res. 2013;210(3):794–9.

    PubMed  Google Scholar 

  31. Moriarty PJ, Lieber D, Bennett A, White L, Parrella M, Harvey PD, Davis KL. Gender differences in poor outcome patients with lifelong schizophrenia. Schizophr Bull. 2001;27(1):103–13.

    PubMed  CAS  Google Scholar 

  32. Riecher-Rössler A, Häfner H, Stumbaum M, Maurer K, Schmidt R. Can estradiol modulate schizophrenic symptomatology? Schizophr Bull. 1994;20(1):203–14.

    PubMed  Google Scholar 

  33. Lindamer LA, Buse DC, Lohr JB, Jeste DV. Hormone replacement therapy in postmenopausal women with schizophrenia: positive effect on negative symptoms? Biol Psychiatry. 2001;49(1):47–51.

    PubMed  CAS  Google Scholar 

  34. Kulkarni J, Riedel A, de Castella AR, Fitzgerald PB, Rolfe TJ, Taffe J, Burger H. Estrogen a potential treatment for schizophrenia. Schizophr Res. 2001;48(1):137–44.

    PubMed  CAS  Google Scholar 

  35. Rao ML, Kölsch H. Effects of estrogen on brain development and neuroprotection–implications for negative symptoms in schizophrenia. Psychoneuroendocrinology. 2003;28 Suppl 2:83–96.

    PubMed  CAS  Google Scholar 

  36. Keenan PA, Ezzat WH, Ginsburg K, Moore GJ. Prefrontal cortex as the site of estrogen’s effect on cognition. Psychoneuroendocrinology. 2001;26(6):577–90.

    PubMed  CAS  Google Scholar 

  37. Krysta K, Murawiec S, Klasik A, Wiglusz MS, Krupka-Matuszczyk I. Sex-specific differences in cognitive functioning among schizophrenic patients. Psychiatr Danub. 2013;25 Suppl 2:S244–6.

    PubMed  Google Scholar 

  38. Myin-Germeys I, Krabbendam L, Delespaul PA, van Os J. Sex differences in emotional reactivity to daily life stress in psychosis. J Clin Psychiatry. 2004;65(6):805–9.

    PubMed  Google Scholar 

  39. Ochoa S, Usall J, Haro JM, Araya S, Autonell J, Busquets E, Gost A. Grupo Nedes. Comparative study of the needs of patients with schizophrenia by gender [Article in Spanish]. Actas Esp Psiquiatr. 2001;29(3):165–71.

    PubMed  CAS  Google Scholar 

  40. Kao YC, Liu YP. Effects of age of onset on clinical characteristics in schizophrenia. BMC Psychiatry. 2010;10:63. doi:10.1186/1471-244X-10-63.

    PubMed  PubMed Central  Google Scholar 

  41. Angermeyer MC, Kühn L, Goldstein JM. Gender and the course of schizophrenia: differences in treated outcomes. Schizophr Bull. 1990;16(2):293–307.

    PubMed  CAS  Google Scholar 

  42. Uggerby P, Nielsen RE, Correll CU, Nielsen J. Characteristics and predictors of long-term institutionalization in patients with schizophrenia. Schizophr Res. 2011;131(1–3):120–6. doi:10.1016/j.schres.2011.03.001. Epub 2011 Apr 1.

    PubMed  Google Scholar 

  43. Opjordsmoen S. Long-term clinical outcome of schizophrenia with special reference to gender differences. Acta Psychiatr Scand. 1991;83(4):307–13.

    PubMed  CAS  Google Scholar 

  44. Ram R, Bromet EJ, Eaton WW, Pato C, Schwartz JE. The natural course of schizophrenia: a review of first-admission studies. Schizophr Bull. 1992;18(2):185–207. Review.

    PubMed  CAS  Google Scholar 

  45. Andreasen NC, Ehrhardt JC, Swayze VW, Alliger RJ, Yuh WT, Cohen G, Ziebell S. Magnetic resonance imaging of the brain in schizophrenia. The pathophysiologic significance of structural abnormalities. Arch Gen Psychiatry. 1990;47(1):35–44.

    PubMed  CAS  Google Scholar 

  46. Nopoulos P, Laum M, Andreasen NC. Sex differences in brain morphology in schizophrenia. Am J Psychiatry. 1997;154:1648–54.

    PubMed  CAS  Google Scholar 

  47. Gur RE, Mozley PD, Shtasel DL, Cannon TD, Gallacher F, Turetsky B, Grossman R, Gur RC. Clinical subtypes of schizophrenia: differences in brain and CSF volume. Am J Psychiatry. 1994;151(3):343–50.

    PubMed  CAS  Google Scholar 

  48. Lewine RRJ, Gulley LR, Risch SC, Jewart R, Houpt JL. Sexual dimorphism, brain morphology and schizophrenia. Schizophr Bull. 1990;16:195–204.

    PubMed  CAS  Google Scholar 

  49. Raine A, Harrison GN, Reynolds GP, Sheard C, Cooper JE, Medley I. Structural and functional characteristics of the corpus callosum in schizophrenics, psychiatric controls and normal controls. A magnetic resonance imaging and neuropsychological evaluation. Arch Gen Psychiatry. 1990;47(11):1060–4.

    PubMed  CAS  Google Scholar 

  50. Ward KE, Friedman L, Wise A, Schulz SC. Meta-analysis of brain and cranial size in schizophrenia. Schizophr Res. 1996;22:197–213.

    PubMed  CAS  Google Scholar 

  51. Haijma SV, Van Haren N, Cahn W, et al. Brain volumes in schizophrenia: a meta-analysis in over 18.000 subjects. Schizophr Bull. 2013;39(5):1129–38.

    PubMed  PubMed Central  Google Scholar 

  52. Gruner P, Christopher C, Robinson DG. Pituitary volume in first episode schizophrenia. Psychiatry Res. 2012;203:100–2.

    PubMed  PubMed Central  Google Scholar 

  53. Romo-Nava F, Hoogenboom WS, Pelavin PE. Pituitary volume in schizophrenia spectrum disorders. Schizophr Res. 2013;146:301–7.

    PubMed  CAS  PubMed Central  Google Scholar 

  54. Cowell PE, Kostianovsky DJ, Gur RC, Turetsky BI, Gur RE. Sex differences in neuroanatomical and clinical correlations in schizophrenia. Am J Psychiatry. 1996;153(6):799–805.

    PubMed  CAS  Google Scholar 

  55. Malla AK, Tarhar J, Norman RMG, Assis L. Computed tomographic findings in schizophrenia: relation with symptom dimensions and sex differences. J Psychiatry Neurosci. 1999;24(2):131–8.

    PubMed  CAS  PubMed Central  Google Scholar 

  56. Seeman MV. Interaction of sex, age, and neuroleptic dose. Compr Psychiatry. 1983;24(2):125–8.

    PubMed  CAS  Google Scholar 

  57. Galderisi S, Bucci P, Üçok A, Peuskens J. No gender differences in social outcome in patients suffering from schizophrenia. Eur Psychiatry. 2012;27(6):406–8. doi:10.1016/j.eurpsy.2011.01.011 (Epub ahead of print).

    PubMed  CAS  Google Scholar 

  58. Gattaz WF, Vogel P, Riecher-Rössler A, Soddu G. Influence of the menstrual cycle phase on the therapeutic response in schizophrenia. Biol Psychiatry. 1994;36(2):137–9.

    PubMed  CAS  Google Scholar 

  59. Seeman MV, Lang M. The role of estrogens in schizophrenia gender differences. Schizophr Bull. 1990;16(2):185–94.

    PubMed  CAS  Google Scholar 

  60. Lane HY, Chang YC, Chang WH, Lin SK, Tseng YT, Jann MW. Effects of gender and age on plasma levels of clozapine and its metabolites: analyzed by critical statistics. J Clin Psychiatry. 1999;60(1):36–40.

    PubMed  CAS  Google Scholar 

  61. Gur RC, Gur RE, Obrist WD, Hungerbuhler JP, Younkin D, Rosen AD, Skolnick BE, Reivich M. Sex and handedness differences in cerebral blood flow during rest and cognitive activity. Science. 1982;217(4560):659–61.

    PubMed  CAS  Google Scholar 

  62. Seeman MV. Neuroleptic expressed prescription for men and women. Soc Pharmacol. 1989;3:219–36.

    Google Scholar 

  63. Haas GL, Glick ID, Clarkin JF, Spencer JH, Lewis AB. Gender and schizophrenia outcome: a clinical trial of an inpatient family intervention. Schizophr Bull. 1990;16(2):277–92.

    PubMed  CAS  Google Scholar 

  64. Davis JA, Goldstein MJ, Nuechterlein KH. Gender differences in family attitudes about schizophrenia. Psychol Med. 1996;26(4):689–96.

    PubMed  CAS  Google Scholar 

  65. Riecher-Rössler A, Häfner H. Gender aspects in schizophrenia: bridging the border between social and biological psychiatry. Acta Psychiatr Scand Suppl. 2000;407:58–62.

    PubMed  Google Scholar 

  66. Galdas PM, Cheater F, Marshall P. Men and health help-seeking behaviour: literature review. J Adv Nurs. 2005;49:616–23.

    PubMed  Google Scholar 

  67. Gayer-Anderson C, Morgan C. Social networks, support and early psychosis: a systematic review. Epidemiol Psychiatr Sci. 2013;22(2):131–46.

    PubMed  CAS  Google Scholar 

  68. Supprian T, Kalus P. Sexual dimorphism of the human brain–a review of the literature. Fortschr Neurol Psychiatr. 1996;64(10):382–9.

    PubMed  CAS  Google Scholar 

  69. Saugstad LF. The maturational theory of brain development and cerebral excitability in the multifactorially inherited manic-depressive psychosis and schizophrenia. Int J Psychophysiol. 1994;18(3):189–203. discussion 187-8.

    PubMed  CAS  Google Scholar 

  70. Downhill Jr JE, Buchsbaum MS, Wei T, Spiegel-Cohen J, Hazlett EA, Haznedar MM, Silverman J, Siever LJ. Shape and size of the corpus callosum in schizophrenia and schizotypal personality disorder. Schizophr Res. 2000;42(3):193–208.

    PubMed  Google Scholar 

  71. Häfner H, an der Heiden W, Hambrecht M, Riecher-Rössler A, Maurer K, Löffler W, Fätkenheuer B. A chapter in systematic schizophrenia research the search for causal explanations for sex differences in age of onset. Nervenarzt. 1993;64(11):706–16. Review. German.

    PubMed  Google Scholar 

  72. Leung A, Chue P. Sex differences in schizophrenia, a review of the literature. Acta Psychiatr Scand Suppl. 2000;401:3–38.

    PubMed  CAS  Google Scholar 

  73. Haus-Seuffert P, Meisterernst M. Mechanisms of transcriptional activation of cAMP-responsive element-binding protein CREB. Mol Cell Biochem. 2000;212(1–2):5–9.

    PubMed  CAS  Google Scholar 

  74. Kölsch H, Lütjohann D, Tulke A, Björkhem I, Rao ML. The neurotoxic effect of 24-hydroxycholesterol on SH-SY5Y human neuroblastoma cells. Brain Res. 1999;818(1):171–5.

    PubMed  Google Scholar 

  75. Kölsch H, Ludwig M, Lütjohann D, Rao ML. Neurotoxicity of 24-hydroxycholesterol, an important cholesterol elimination product of the brain, may be prevented by vitamin E and estradiol-17beta. J Neural Transm. 2001;108(4):475–88.

    PubMed  Google Scholar 

  76. Hughes ZA, Liu F, Marquis K, Muniz L, Pangalos MN, Ring RH, Whiteside GJ, Brandon NJ. Estrogen receptor neurobiology and its potential for translation into broad spectrum therapeutics for CNS disorders. Curr Mol Pharmacol. 2009;2:215–36.

    PubMed  CAS  Google Scholar 

  77. Taylor GT, Maloney S, Dearborn J, et al. Hormones in the mentally disturbed brain: steroids and peptides in the development and treatment of psychopathology. Cent Nerv Syst Agents Med Chem. 2009;9(4):331–60.

    PubMed  CAS  Google Scholar 

  78. Kulkarni J, Hayes E, Gavrilidis E. Hormones and schizophrenia. Curr Opin Psychiatry. 2012;25:89–95.

    PubMed  Google Scholar 

  79. Kulkarni J, Gavrilidis E, Worsley R, Hayes E. Role of estrogen treatment in the management of schizophrenia. CNS Drugs. 2012;26(7):549–57.

    PubMed  CAS  Google Scholar 

  80. Kendell RE, Chalmers JC, Platz C. Epidemiology of puerperal psychoses. Br J Psychiatry. 1987;150:662–73.

    PubMed  CAS  Google Scholar 

  81. Riecher-Rossler A, Seeman MV. Oestrogens and schizophrenia: introduction. Arch Womens Ment Health. 2002;5(3):91–2.

    PubMed  CAS  Google Scholar 

  82. Seeman MV. Psychopathology in women and men: focus on female hormones. Am J Psychiatry. 1997;154(12):1641–7.

    PubMed  CAS  Google Scholar 

  83. Sommer IE, van Westrhenen R, Begemann MJ, de Witte LD, Leucht S, Kahn RS. Efficacy of anti-inflammatory agents to improve symptoms in patients with schizophrenia: an update. Schizophr Bull. 2014;40(1):181–91.

    PubMed  Google Scholar 

  84. Kulkarni J, de Castella A, Smith D, Taffe J, Keks N, Copolov D. A clinical trial of the effects of estrogen in acutely psychotic women. Schizoph Res. 1996;20(3):247–52.

    CAS  Google Scholar 

  85. Kinon BJ, Gilmore JA, Liu H, Halbreich UM. Prevalence of hyperprolactinemia in schizophrenic patients treated with conventional antipsychotic medications or risperidone. Psychoneuroendocrinology. 2003;28 Suppl 2:55–68.

    PubMed  CAS  Google Scholar 

  86. O'Keane V. Review antipsychotic-induced hyperprolactinaemia, hypogonadism and osteoporosis in the treatment of schizophrenia. J Psychopharmacol. 2008;22(2 Suppl):70–5.

    PubMed  Google Scholar 

  87. Dursun SM, Wildgust HJ, Strickland P, Goodwin GM, Citrome L, Lean M. The emerging physical health challenges of antipsychotic associated hyperprolactinaemia in patients with serious mental illness. J Psychopharmacol. 2008;22(2 Suppl):3–5.

    PubMed  Google Scholar 

  88. Meaney AM, Smith S, Howes OD, O'Brien M, Murray RM, O'Keane V. Effects of long-term prolactin-raising antipsychotic medication on bone mineral density in patients with schizophrenia. Br J Psychiatry. 2004;184:503–8.

    PubMed  CAS  Google Scholar 

  89. Montejo AL. Review prolactin awareness: an essential consideration for physical health in schizophrenia. Eur Neuropsychopharmacol. 2008;18 Suppl 2:S108–14.

    PubMed  CAS  Google Scholar 

  90. Ghadirian AM, Chouinard G, Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J Nerv Ment Dis. 1982;170(8):463–7.

    PubMed  CAS  Google Scholar 

  91. Bobes J, Arango C, Aranda P, Carmena R, Garcia-Garcia M, Rejas J, CLAMORS Study Collaborative Group. Cardiovascular and metabolic risk in outpatients with schizophrenia treated with antipsychotics: results of the CLAMORS Study. Schizophr Res. 2007;90(1–3):162–73.

    PubMed  Google Scholar 

  92. Boke O, Aker S, Sarisoy G, Saricicek EB, Sahin AR. Prevalence of metabolic syndrome among inpatients with schizophrenia. Int J Psychiatry Med. 2008;38(1):103–12.

    PubMed  Google Scholar 

  93. Fernandez-Egea E, Bernardo M, Donner T, Conget I, Parellada E, Justicia A, Esmatjes E, Garcia-Rizo C, Kirkpatrick B. Metabolic profile of antipsychotic-naive individuals with non-affective psychosis. Br J Psychiatry. 2009;194(5):434–8.

    PubMed  PubMed Central  Google Scholar 

  94. Seeman MV. Women and psychosis. Womens Health. 2012;8(2):215–24.

    Google Scholar 

  95. Seeman MV. Secondary effects of antipsychotics: women at greater risk than men. Schizophr Bull. 2009;35(5):937–48.

    PubMed  PubMed Central  Google Scholar 

  96. Seeman MV. Antipsychotic-induced somnolence in mothers with schizophrenia. Psychiatr Q. 2012;83(1):83–9. doi:10.1007/s11126-011-9185-z (Epub ahead of print).

    PubMed  Google Scholar 

  97. Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Pro-arrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging. 2009;26(12):997–1012.

    PubMed  CAS  Google Scholar 

  98. Yasui-Furukori N, Saito M, Nakagami T, et al. Gender-specific prolactin response to antipsychotic treatments with risperidone and olanzapine and its relationship to drug concentrations in patients with acutely exacerbated schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry. 2010;34(3):537–40.

    PubMed  CAS  Google Scholar 

  99. Seeman MV. Preventing breast cancer in schizophrenia. Acta Psychiatr Scand. 2011;123(2):107–17.

    PubMed  CAS  Google Scholar 

  100. VanOs J, Walsh E, van Horn E, Tattan T, Bale R, Thompson SG. Tardive dyskinesia in psychosis: are women really more at risk? UK700 Group. Acta Psychiatr Scand. 1999;99(4):288–93.

    CAS  Google Scholar 

  101. Os V, et al. Tardive dyskinesia: who is at risk? Acta Psychiatr Scand. 1997;96(3):206–16.

    PubMed  Google Scholar 

  102. Fink G, Sumner E, McQueen JK, Wilson H, Rosie R. Sex steroid control of mood, mental state and memory. Clin Exp Pharmacol Physiol. 1998;25(10):764–75. Review.

    PubMed  CAS  Google Scholar 

  103. Akhondzadeh S, Nejatisafa AA, Amini H, Mohammadi MR, Larijani B, Kashani L, Raisi F, Kamalipour A. Adjunctive estrogen treatment in women with chronic schizophrenia: a double-blind, randomized, and placebo-controlled trial. Prog Neuropsychopharmacol Biol Psychiatry. 2003;27(6):1007–12.

    PubMed  CAS  Google Scholar 

  104. Smith S. Gender differences in antipsychotic prescribing. Int Rev Psychiatry. 2010;22(5):472–84. doi:10.3109/09540261.2010.515965. Review.

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Alava University Hospital, Vitoria, Spain

    Iñaki Zorrilla

  2. Department of Psychiatry, Alava University Hospital, Vitoria, Spain

    Saioa López-Zurbano, Ana Isabel Cano & Ana González-Pinto

  3. University of the Basque Country UPV/EHU, Guipúzcoa, Spain

    Ana González-Pinto

Authors
  1. Iñaki Zorrilla
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Saioa López-Zurbano
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ana Isabel Cano
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Ana González-Pinto
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Iñaki Zorrilla .

Editor information

Editors and Affiliations

  1. Dept. of Psychiatry, Hospital Universitario de Alava, Victoria, Spain

    Margarita Sáenz-Herrero

Rights and permissions

Reprints and permissions

Copyright information

© 2015 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Zorrilla, I., López-Zurbano, S., Cano, A.I., González-Pinto, A. (2015). Schizophrenia and Gender. In: Sáenz-Herrero, M. (eds) Psychopathology in Women. Springer, Cham. https://doi.org/10.1007/978-3-319-05870-2_27

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-05870-2_27

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-05869-6

  • Online ISBN: 978-3-319-05870-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation